Mark Gillespie, MD
Ophthalmology · Fort Myers, FLNPI 1942277280
Payments from drug & device makers
Across 156 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Aerie Pharmaceuticals, Inc.$776
- AbbVie$688
- Johnson & Johnson Surgical Vision, Inc.$363
- Rxsight Inc$285
- Bausch & Lomb, A Division Of Bausch Health US, LLC$215
- plus $1K from 20 others
What the payments were for
- Consulting fees$60012%
- Food & beverage$4,38787%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 26 | $1,275 |
| Aerie Pharmaceuticals, Inc. | 7 | $776 |
| AbbVie(2 entities) | 34 | $688 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $363 |
| Rxsight Inc | 9 | $285 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $215 |
| Ocular Therapeutix, Inc. | 3 | $186 |
| Shire North American Group Inc | 3 | $180 |
| Bausch & Lomb Americas Inc. | 8 | $145 |
| Neurotech Pharmaceuticals, Inc. | 1 | $137 |
| Sun Pharmaceutical Industries Inc. | 8 | $134 |
| Regeneron Healthcare Solutions, Inc. | 8 | $118 |
| Novartis | 7 | $106 |
| Biotissue Holdings Inc. | 6 | $52 |
| Rayner Intraocular Lenses Limited | 2 | $50 |
| Astellas Pharma US Inc | 2 | $46 |
| Harrow Eye, LLC | 2 | $45 |
| Genentech USA, Inc. | 3 | $41 |
| Glaukos Corporation | 1 | $32 |
| Sight Sciences, Inc. | 2 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $30 |
| Dompe US, Inc. | 1 | $27 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Amgen | 1 | $15 |
| Lombart Brothers, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,032 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 11 | $19,556 |
| ProlensaBromfenac Sodium | 52 | $17,871 |
| VyzultaLatanoprostene Bunod | 36 | $16,499 |
| LumiganBimatoprost | 23 | $8,113 |
| Prednisolone Acetate | 196 | $5,628 |
| Lotemax SmLoteprednol Etabonate | 17 | $4,319 |
| MoxifloxacinMoxifloxacin Hcl | 170 | $3,786 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,367 |
| Timolol Maleate | 105 | $1,842 |
| Latanoprost | 185 | $1,665 |
| Ketorolac Tromethamine | 24 | $1,189 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 62 | $1,156 |
| Dorzolamide Hcl | 17 | $431 |
| Brimonidine Tartrate | 37 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $688 | $27,66934 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $215 | $22,19069 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $145 | $16,49936 claims |
| AlconSimbrinza | $1,275 | $3,36717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Fort Myers
- Stephen SmithFort Myers$591K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.